Journal of the National Comprehensive Cancer Network : JNCCN · 2022
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gerds Aaron T, Gotlib Jason, Ali Haris, Bose Prithviraj, Dunbar Andrew, Elshoury Amro, George Tracy I, Gundabolu Krishna, Hexner Elizabeth, Hobbs Gabriela S, Jain Tania, Jamieson Catriona, Kaesberg Paul R, Kuykendall Andrew T, Madanat Yazan, McMahon Brandon, Mohan Sanjay R, Nadiminti Kalyan V, Oh Stephen, Pardanani Animesh, Podoltsev Nikolai, Rein Lindsay, Salit Rachel, Stein Brady L, Talpaz Moshe, Vachhani Pankit, Wadleigh Martha, Wall Sarah, Ward Dawn C, Bergman Mary Anne, Hochstetler Cindy
Аннотация
The classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for the management of MPN in adults. The Guidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.